Focus groups and surveys are biased by pre-set questions. Ethnographic research—observing patients in their daily lives—uncovers their true hopes and needs, which can fundamentally transform a drug's development and go-to-market strategy.
"Yes, but" kills energy and negates ideas. The simple improv-derived switch to "Yes, and" builds momentum and fosters co-creation. This small linguistic change can fundamentally improve outcomes in teams, families, and businesses.
Public-private partnerships can revolutionize access. The MMV model uses open-source discovery, co-financing, and patent-free distribution in the Global South via pharma partners. This de-risks development and ensures immediate access in endemic countries.
Traditional leadership programs anoint high-potentials, creating a fear of failure. Improv provides a practice ground for recovering from setbacks, building resilience for when things inevitably go wrong in high-stakes environments.
Technical proficiency in modeling and dossiers isn't enough. The critical, often-missed skill for senior market access professionals is translating complex evidence into a compelling story that aligns and motivates non-technical internal functions.
Well-intentioned programs developed in Western hubs are "bound to fail" if they don't involve local stakeholders from the very beginning. Early co-creation with those who will prescribe, distribute, and finance the product is essential for sustainability.
Quality of life in old age (“healthspan”) depends more on purpose and social connection than longevity. Retirement often eliminates these, making it one of the unhealthiest decisions one can make. Continued engagement is a powerful antidote to loneliness.
Laughter isn't just for fun; it's a powerful tool for connection. It quickly builds rapport and trust, creating the psychological safety required for effective teamwork and collaboration, especially in high-pressure environments.
The huge price gap for drugs like semaglutide reflects fundamentally different social contracts: the US is a libertarian system prioritizing individual choice, while Europe uses universal systems that limit access to a negotiated basket of drugs.
Market access isn't a launch activity; it's a pre-launch strategy. Its most crucial input is during early clinical trial design, ensuring the right comparators and endpoints are chosen to satisfy payers years down the line. Post-hoc fixes are impossible.
The traditional advice to "pick a lane" is becoming obsolete. In an era of disruption from forces like AI, a multi-hyphenate career built on curiosity provides a broader skillset and adaptability that is more valuable than deep, narrow specialization.